Answers are grounded in this paper and cite their sources.
Subgroup analysis reveals effective prophylaxis reduces bleeding rates in type 3 von Willebrand disease patients, suggesting significant clinical benefits.
Objectives The WIL‐31 study demonstrated efficacy and safety of prophylaxis with the plasma‐derived von Willebrand factor/factor VIII concentrate wilate in von Willebrand disease (VWD) of all types and was the only prospective study with an on‐demand run‐in study as an intra‐individual comparator. This subgroup analysis examines the efficacy of wilate prophylaxis in patients with type 3 VWD in WIL‐31. Methods Patients received 20–40 IU/kg wilate prophylaxis 2–3 times weekly for 12 months. Results Twenty‐two patients in WIL‐31 had type 3 VWD. Mean total annualized bleeding rate (ABRs) during on‐demand versus prophylaxis was 37.1 versus 5.2 (86% reduction). During prophylaxis, 115 bleeds occurred, most (95%) of which were minor; the most common bleeding site was the nose (40% of bleeds). Mean overall spontaneous ABRs during on‐demand versus prophylaxis were 26.5 versus 2.8 (89% reduction); mean treated spontaneous ABRs were 20.3 versus 1.4, respectively (93% reduction). ABRs were reduced further during the second 6 months of prophylaxis versus the first 6 months. Results were consistent in subgroups by age. No serious adverse events related to study treatment and no thrombotic events were observed. Conclusions Prophylaxis with wilate was effective and well tolerated in patients with type 3 VWD, in all age groups. Trial Registration: NCT04052698; https://clinicaltrials.gov/study/NCT04052698
No takes yet. Share an insight, caveat, or question.
Khayat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: